Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib plus TGI/CIV for relapsed or refractory pediatric rhabdomyosarcoma
ChiCTR2500096689Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib, paclitaxel, gemcitabine, ifosfamide, cyclophosphamide and 2 more in rhabdomyosarcoma (RMS), sponsored by Shandong First Medical University. Primary endpoint: Objective response rate. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
pazopanibpaclitaxelgemcitabineifosfamidecyclophosphamide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on ChiCTR2500096689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096689.